Security key
74065P101
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)
CUSIP: 74065P101
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 30,772,368
- Total 13F value
- $105,239,465
- Share change
- +2,321,660
- Put/Call ratio
- 0%
- SEC-reported price per share
- $3.42
- Number of holders
- 55
- Value change
- +$8,578,948
- Number of buys
- 30
- Number of sells
- 16
- Shares outstanding
- 64,968,808
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
55
Top holders
10
PRLD full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q3 2025
Prelude Therapeutics Inc SEC filings
Prelude Therapeutics Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74065P101
Recent filing periods:
Ownership snapshot
Top reported holders of PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Vaddi Krishna
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
05 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 13%
13D/G row: Vaddi Krishna
Showing 1-6 of 15 holder rows.
Quick read
Vaddi Krishna leads the comparable SEC ownership view at 13%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vaddi Krishna's linked filing trail.
Comparable ownership
Top 5
Vaddi Krishna
13%
INCYTE CORP
9.9%
Sean P. Brusky
0.15%
ORBIMED ADVISORS LLC
17%
BAKER BROS. ADVISORS LP
16%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vaddi Krishna |
13D/G
3/4/5
CEO, Director
|
13%
|
$19,562,376
6,745,647 shares
|
+$1,008,643 | 31 Dec 2025 |
| INCYTE CORP |
13D/G
|
9.9%
|
$6,295,859
4,372,124 shares
|
$0 | 03 Nov 2025 |
| Sean P. Brusky |
3/4/5
Chief Business Officer
|
0.15%
|
$278,000
100,000 shares
|
— | 05 Mar 2026 |
| ORBIMED ADVISORS LLC |
13F
Company
|
17%
|
$31,636,842
10,909,256 shares
|
— | 31 Dec 2025 |
| BAKER BROS. ADVISORS LP |
13F
Company
|
16%
|
$29,359,090
10,123,824 shares
|
— | 31 Dec 2025 |
| VANGUARD GROUP INC |
13F
Company
|
2.2%
|
$4,100,559
1,413,986 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
55
Shares
30,772,368
Rows available
55
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q3 2025 Across Filers
Q3 2025 holders
45
Q1 2026 holders
55
Holder diff
10
| Investor | Q3 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q3 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend